Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) have been given a consensus rating of “Buy” by the five brokerages that are covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have covered the stock in the last year is $10.00.
Separately, HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Carisma Therapeutics in a research report on Wednesday, November 29th.
Carisma Therapeutics Stock Performance
Carisma Therapeutics (NASDAQ:CARM – Get Free Report) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.07. The business had revenue of $3.83 million for the quarter. On average, sell-side analysts forecast that Carisma Therapeutics will post -2.64 earnings per share for the current fiscal year.
Institutional Trading of Carisma Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Barclays PLC acquired a new stake in shares of Carisma Therapeutics during the second quarter worth $47,000. Citigroup Inc. acquired a new stake in shares of Carisma Therapeutics during the second quarter worth $70,000. California State Teachers Retirement System acquired a new stake in shares of Carisma Therapeutics during the second quarter worth $78,000. Wells Fargo & Company MN raised its position in Carisma Therapeutics by 1,957.9% during the second quarter. Wells Fargo & Company MN now owns 10,598 shares of the company’s stock valued at $93,000 after buying an additional 10,083 shares during the period. Finally, Tower Research Capital LLC TRC raised its position in Carisma Therapeutics by 534.8% during the third quarter. Tower Research Capital LLC TRC now owns 10,982 shares of the company’s stock valued at $46,000 after buying an additional 9,252 shares during the period. Institutional investors own 32.22% of the company’s stock.
About Carisma Therapeutics
Carisma Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases. The company's clinical and pre-clinical programs include CT-0508 and CT-0525 targeting HER2 overexpressing tumors; and CT-1119, a CAR-Monocyte for mesothelin overexpressing solid tumors.
- Five stocks we like better than Carisma Therapeutics
- What is a Special Dividend?
- What are specialty REITs? How to invest in them
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Miso Robotics stock: Is an IPO coming soon?
- What are stock market earnings reports?
- Insiders are selling these hot stocks on track for higher prices
Receive News & Ratings for Carisma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carisma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.